Molecular signaling in the regulation of dendritic cell function
Molecular signaling in the regulation of dendritic cell function
批准号:
RGPIN-2015-03671
负责人:
Amrani, Abdelaziz
金额:
$2.19万
依托单位:
依托单位国家:
加拿大
项目类别:
Discovery Grants Program - Individual
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-01-01 至 2019-12-31
中文摘要
***树突状细胞(dc)是协调免疫反应的关键角色。dc成熟状态对T细胞功能有深远的影响。成熟的dc (mDCs)可以诱导有效的T细胞应答,而不成熟的dc (iDCs)和半成熟的dc (smDCs)则可以促进和维持T细胞的耐受性。驱动dc产生免疫原性或调节功能的分子机制尚不完全清楚。我们用低剂量的GM-CSF或GM-CSF+IL-4从NOD和Balb/c小鼠的骨髓中生成了dc。我们发现用GM-CSF生成的dc具有半成熟表型,产生大量的IL-10但较少的IL-12,并且激活CD8+ T细胞的能力降低。GM-CSF+IL-4生成的lps激活dc完全成熟,产生大量IL-12但较少IL-10,并诱导CD8+ T细胞的强增殖。Western blot分析显示MAP激酶ERK 1/2在smdc中持续激活,而在mDCs中没有。我们还发现ERK1/2激活参与IL-10的产生而不影响DCs表型。NF-?的分析B成分p52、p65和RelB的研究表明,p52/p65在smdc中优先激活,而p52/RelB在mdc中优先激活。这些结果提示NF?B复合物和ERK1/2的激活参与了成熟抗性dc的发展及其IL-10产量的增加。CREB、AP1和C/EBP的结合能力以及它们与NF-kB组分的相互作用表明,C/EBPß亚型在smdc中被激活,而在mDCs中不被激活。这些结果表明,Rel/B和C/EBPß在DCs成熟阶段的调控中起关键作用。***理性C/EBPß转录因子参与巨噬细胞的分化和活化。例如,来自C/EBPß-KO小鼠的巨噬细胞产生较少的IL-12,不能诱导Th1反应。此外,我们的初步数据支持这样一种观点,即在smDC中被激活的C/EBPß亚型在调节性smDC的产生中发挥了关键作用。***假设C/EBPß转录因子亚型及其调控因子触发前体dc (pDCs)选择性分化为调节性smDC或效应型mDCs。***目的:***1)探讨C/EBPß在smdc或mDCs产生中的相对作用。***2)鉴定C/EBPß同工异构体伙伴,触发pDCs分化为smDC和mDCs。***3)研究C/EBPß LAP或/和LAP*的激活物异构体或其抑制剂异构体LIP是否调节smDCs和mDCs的表型和功能。***意义:了解控制dc分化为调节性smdc或效应型mdc的机制将提高我们对基础免疫学的认识,并可能有助于设计新的靶向治疗方法来治疗自身免疫性疾病和病毒感染。**
英文摘要
***Dendritic cells (DCs) are key players in the orchestration of the immune response. DCs maturation status has a profound effect on T cell functions. Mature DCs (mDCs) are known to induce an effective T cell response whereas immature (iDCs) and semimature DCs (smDCs) promote and maintain T cell tolerance. The molecular mechanisms that drive DCs to immunogenic or to regulatory functions are not fully known. We have generated DCs from bone marrow of NOD and Balb/c mice either with low doses of GM-CSF or with GM-CSF+IL-4. We found that DCs generated with GM-CSF had a semimature phenotype, produced high amounts of IL-10 but less IL-12, and had a decrease capacity to activated CD8+ T cells. LPS-activated DCs generated with GM-CSF+IL-4 were fully mature, produced large amounts of IL-12 but less IL-10 and induce strong proliferation of CD8+ T cells. Western blot analysis revealed a sustained activation of MAP kinase ERK 1/2 in smDCs but not in mDCs. We also found that ERK1/2 activation is involved in IL-10 production without affecting DCs phenotype. The analysis of NF-?B components p52, p65 and RelB, showed that p52/p65 is preferentially activated in smDCs whereas p52/RelB is preferentially activated in mDCs. These results suggest that the absence of RelB in NF?B complex and that the activation of ERK1/2 are involved in the development of maturation-resistant DCs and their increased IL-10 production. The analysis of the binding capacity of CREB, AP1 and C/EBP which are known for their contribution to increase the expression of costimulatory molecules, and their interaction with NF-kB component, revealed that C/EBPß isoform is activated in smDCs but not in mDCs. These results suggest that Rel/B and C/EBPß played a key role in the control of maturation stage of DCs.***Rational The C/EBPß transcription factors are known to be involved in differentiation and activation of macrophages. For example, macrophages from C/EBPß-KO mice produced less IL-12 and could not induce a Th1 response. Furthermore, our preliminary data support the notion that C/EBPß isoforms, which were activated in smDC, played a critical role in the generation of regulatory smDCs.***Hypothesis C/EBPß transcription factor isoforms and their regulators trigger the selective differentiation of precursor DCs (pDCs) into regulatory smDC or effector mDCs.***Objectives:***1) to dissect relative role of C/EBPß in the generation of smDcs or mDCs. ***2) to identify C/EBPß isoforms partners that trigger differentiation of pDCs into smDC and mDCs. ***3) to investigate whether the activator isoforms of C/EBPß LAP or/and LAP* or its inhibitor isoform LIP regulate smDCs and mDCs phenotypes and functions. ***Significance: Understanding the mechanisms that control differentiation of DCs into regulatory smDCs or effector mDCs will improve our knowledge of basic immunology and may help to design new targeted therapeutics for the treatment of autoimmune diseases and viral infections. **
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular signaling in the regulation of dendritic cell function
-
批准号:RGPIN-2015-03671
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.19万
-
财政年份:2019
-
负责人:Amrani, Abdelaziz
-
依托单位:
Molecular signaling in the regulation of dendritic cell function
-
批准号:RGPIN-2015-03671
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.19万
-
财政年份:2017
-
负责人:Amrani, Abdelaziz
-
依托单位:
Molecular signaling in the regulation of dendritic cell function
-
批准号:RGPIN-2015-03671
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.19万
-
财政年份:2016
-
负责人:Amrani, Abdelaziz
-
依托单位:
Molecular signaling in the regulation of dendritic cell function
-
批准号:RGPIN-2015-03671
-
项目类别:Discovery Grants Program - Individual
-
资助金额:$2.19万
-
财政年份:2015
-
负责人:Amrani, Abdelaziz
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Foxc2介导Syap1/Akt信号通路调控破骨/成骨细胞分化促进颞下颌关节骨关节炎的机制研究
-
批准号:82370979
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张善勇
-
依托单位:
丁酸梭菌代谢物(如丁酸、苯乳酸)通过MYC-TYMS信号轴影响结直肠癌化疗敏感性的效应及其机制研究
-
批准号:82373139
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:李孟鸿
-
依托单位:
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
-
批准号:82371726
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李文
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
运用3D打印和生物反应器构建仿生尿道模型探索Hippo-YAP信号通路调控尿道损伤修复的机制研究
-
批准号:82370684
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:傅强
-
依托单位:
“肠—肝轴”PPARα/CYP8B1胆汁酸合成信号通路在减重手术改善糖脂代谢中的作用与机制
-
批准号:82370902
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:田景琰
-
依托单位:
GASP-1通过Myostatin信号通路调控颏舌肌功能的作用及机制研究
-
批准号:82371131
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:易红良
-
依托单位:
PCBP1和PCBP2调控cGAS的相变和酶活的机制研究
-
批准号:32370928
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:孙钦秒
-
依托单位:
组蛋白乙酰化修饰ATG13激活自噬在牵张应力介导骨缝Gli1+干细胞成骨中的机制研究
-
批准号:82370988
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:经典
-
依托单位:
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
-
批准号:82371738
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郑英霞
-
依托单位: